TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

As budget woes persist, BPJS delists cancer drugs

Gemma Holliani Cahya (The Jakarta Post)
Premium
Jakarta
Tue, February 26, 2019

Share This Article

Change Size

As budget woes persist, BPJS delists cancer drugs BPJS Kesehatan spent Rp 8.7 trillion in 2014, while the number hit Rp 18 trillion in 2018. It spent almost Rp 3 trillion for cancer treatments, the second largest amount after cardiovascular at Rp 9.4 trillion. (Shutterstock/Aleksandar Karanov)

I

n another effort to curb the worsening deficit in the state health insurance, the government has attempted to remove more cancer medicines from its coverage, which may put the lives of patients on the line.

The Health Ministry has issued a new ministerial decree on the national formulary that excludes bevacizumab, a medication used mostly for targeted chemotherapy to treat metastatic colorectal cancer, from the list of medicines covered under the National Health Insurance (JKN) scheme.

The new regulation that will be effective on March 1 also stops the use of cetuximab, also used for colorectal cancer. The new formulary stipulates that it can only be used to treat Squamous cell carcinoma, also known as head and neck cancer.

Husain Nurisman, 45, who survived metastatic colorectal cancer last year thanks to the combination of both medicines, said he was now more afraid if his cancer would reoccur.

Although Husain is covered by the insurance scheme under the Health Care and Social Security Agency (BPJS Kesehatan), he relied on financial assistance from his office that offered to cover all of his expenses.

Husain said his office had to spend Rp 60 million (US$4,300) for each targeted therapy session. Last year, he underwent 10 treatments in five months and his office covered the Rp 600 million bill.

“I don’t know what I will do if one day the cancer returns when I have retired. If at that time these two medicines are not covered by the JKN, I think I will ask the doctors to euthanize me instead. My family will lose everything if they have to pay and I don’t want to see them suffer because of me,” he said.

to Read Full Story

  • Unlimited access to our web and app content
  • e-Post daily digital newspaper
  • No advertisements, no interruptions
  • Privileged access to our events and programs
  • Subscription to our newsletters
or

Purchase access to this article for

We accept

TJP - Visa
TJP - Mastercard
TJP - GoPay

Redirecting you to payment page

Pay per article

As budget woes persist, BPJS delists cancer drugs

Rp 29,000 / article

1
Create your free account
By proceeding, you consent to the revised Terms of Use, and Privacy Policy.
Already have an account?

2
  • Palmerat Barat No. 142-143
  • Central Jakarta
  • DKI Jakarta
  • Indonesia
  • 10270
  • +6283816779933
2
Total Rp 29,000

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.